You have accessJournal of UrologyInfections/Inflammation/Cystic Disease of the Genitourinary Tract: Interstitial Cystitis II1 Apr 2017MP29-18 BOTULINUM TOXIN A BLADDER INJECTION IN THE TREATMENT OF BLADDER PAIN SYNDROME/IC: TRYING TO STANDARDIZE THE TECHNIQUE Cristina Gutiérrez, Carlos Errando, Nicolas Nervo, Pedro Araño, and Humberto Villavicencio Cristina GutiérrezCristina Gutiérrez More articles by this author , Carlos ErrandoCarlos Errando More articles by this author , Nicolas NervoNicolas Nervo More articles by this author , Pedro ArañoPedro Araño More articles by this author , and Humberto VillavicencioHumberto Villavicencio More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.930AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Bladder Pain Syndrome/Interstitial cystitis (BPS) is a very complex entity with no clear etiology. Intravesical Botulinum Toxin is accepted as a 4th line treatment in BPS. The injection procedure is not standardized yet. The aim of the present study is to evaluate the efficacy of Botulinum Toxin A (BoNT A) intravesical injections in patients with BPS after a standarized injection procedure. Secondarily, we evaluate the complications, duration of response, and the effect of adding hydrodistension (HD) during the procedure. METHODS Fourty one patients with BPS treated between January 2008 to march 2015 were retrospectively evaluated. All patients received 200 UI of BoNT A injected under cystoscopic control: 100 UI in the trigone plus 100 UI in the detrusor. In 26 patients HD was also performed. Three days voiding chart, Visual Analogue Scale (VAS) for pain, Global Response Assessment (GRA) and urodynamic parameters were evaluated at baseline and after treatment. RESULTS After a mean follow-up of 36 months, 25 patients (61%) reported subjective improvement (-3 points in VAS) lasting during 7 months as an average (range 3-18). Eight patients (20%) reported total relief of pain (VAS = 0). Daytime and nighttime urinary frequencies were reduced, reaching statistically significance only at night (from 7 to 4 times p < 0.001). Functional bladder capacity measured by voiding chart increased significantly (from 73 to 115 ml p < 0.003). Mean voided volume at uroflowmetry increased significantly (from 100 to 191 ml p < 0.001). Four patients reported incomplete bladder emptying, however there were no significant increase in postvoid residual volume. The comparison between HD and nonHD groups of patients did not show a significant difference in objective parameters. However, the HD group showed a significantly better GRA (7 versus 4 p <0.02). CONCLUSIONS The proposed procedure of BoNT A injection (100UI trigone + 100 UI detrusor plus HDT) was effective and safe in treating refractory BPS in our study improving significantly the nighttime frequency, voided volume in voiding chart and uroflowmetry, and relieving totally the pain in 20% of cases. HD provides a better subjective response without increasing morbidity. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e387-e388 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Cristina Gutiérrez More articles by this author Carlos Errando More articles by this author Nicolas Nervo More articles by this author Pedro Araño More articles by this author Humberto Villavicencio More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...